Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults

• Published in: Antiviral research Vol. 123; pp. 114 - 119
• Main Authors: Zenilman, Jonathan M., Fuchs, Edward J., Hendrix, Craig W., Radebaugh, Christine, Jurao, Robert, Nayak, Seema U., Hamilton, Robert G., McLeod Griffiss, J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2015
• Subjects: Administration, Inhalation; Adult; Antibodies - blood; Antiviral Agents - administration & dosage; DAS-181; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Female; Healthy Volunteers; Humans; Immunoglobulin G - blood; Influenza; Male; Neuraminidase - administration & dosage; Neuraminidase - adverse effects; Parainfluenza; Placebos - administration & dosage; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Sialidase; DAS-181; Parainfluenza; Influenza; Sialidase

•DAS181 is a sialidase with activity against influenza and parainfluenza.•Daily inhalation of 20mg/day was well tolerated for up to seven days.•Daily inhalation of 20mg/day for >7days was associated with respiratory toxicity.•Longer dose schedules were associated with immunogenicity. DAS181, (stu...